Oridonin New

Biological Activity

High affinity NLRP3 inflammasome inhibitor (K_d = 52.5 nM). Forms covalent bind within NACHT domain and blocks interaction of NLRP3 with NEK7 to inhibit assembly and activation of inflammasome. Inhibits glial activation, decreases inflammatory cytokine release, attenuates synaptic loss and improves behavioural deficits in Aβ1-42 treated mice. Also displays anti-cancer properties in various cancer cell lines.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Oridonin attenuates Aβ1-42-induced neuroinflammation and inhibits NF-κB pathway.
   Wang et al.
   PLoS One, 2014;9:e104745
2. Oridonin attenuates synaptic loss and cognitive deficits in an Aβ1-42-induced mouse model of alzheimer's disease.
   Wang et al.
   PLoS One, 2016;11:e0151397
3. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.
   He et al.
   Nat.Commun., 2018;9:2550
4. Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma.
   Wang et al.
   Eur.J.Pharmacol., 2017;815:282
5. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells.
   Yao et al.
   Cell Death Dis., 2017;8:e2633

Product Datasheets